MM-372 A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM): SUCCESSOR-1

Autor: Richardson, Paul G., Badelita, Sorina N., Besemer, Britta, Boudreault, Jean-Samuel, Byun, Ja Min, Cerchione, Claudio, Gatt, Moshe E., Gibbs, Simon, Koroda, Junya, Martinez-Lopez, Joaquín, Min, Chang-Ki, Orlowski, Robert Z., Quach, Hang, Raab, Marc S., Weisel, Katja, Zhou, Xin, Amatangelo, Michael, Wang, Yue, Hwang, Soo Jeong, Emerson, Joshua, Koo, Phillip, Rocci, Alberto, Katz, Jessica
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S495-S496
Databáze: ScienceDirect
Externí odkaz: